Investor Alert: Entheon Biomedical - Treating Addiction

December 16, 2021

Entheon is powered by an unwavering commitment to significantly improve the odds of beating addiction for people who otherwise might now

Entheon Biomedical is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products ("DMT Products") for the purposes of treating addiction and substance use disorders.

Entheon is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming human trial, EBRX-101 is one of the most comprehensive studies of DMT to date and will evaluate the pharmacodynamics, pharmacokinetics, and safety profile of DMT in order to advance it as a therapeutic for addiction disorder.

In addition, Entheon is focusing on the identification, analysis and predictive use of genetics and EEG biomarkers to develop a treatment system that personalizes patient care through all stages of the treatment continuum.

For more information on Entheon Biomedical Corp. (CSE: ENBI, OTCQB: ENTBF) please click the request investor info button.

You might also like

Entheon Biomedical: Looking to Remedy the Root Causes of Addiction

With an expert team of scientists and world-class advisors, Entheon Biomedical is looking to remedy the root causes of addiction. Additionally, The co …

Small Pharma: Mental Health Solutions with Psychedelics

Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on …

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!